AllDocs -> cancers

Corporate Medical Policy Bone Marrow Transplant for Multiple Myeloma and Primary Amyloidosis File Name: bone_marrow_transplant_for_multiple_myeloma_and_primary_amyloidosis Policy Number: SUR6090.14 Origination: 2/2001 Last Review: 2/2003 Next Review: 2/2005 Description of Procedure or Service "High-dose chemotherapy" (HDC) involves the administration of cytotoxic agents for the treatment of can- cer. It uses doses several times greater than the standard therapeutic dose. In some cases, whole body or localized radiotherapy is also given and is included in the term HDC. The rationale for HDC is that many cytotoxic agents act according to a steep dose-response curve . Thus, small increments in dosage will result in relatively large increases in tumor cell kill. Increasing the dosage also increases the incidence and severity ...

2 C L E V E L A N D C L I N I C T A U S S I G C A N C E R C E N T E R COVER STORY A TEAM OF C LEVELAND C LINIC PHYSICIANS , led by oncologist Mohamad Hussein, M.D., is inves- tigating Revimid for patients with multi- ple myeloma in three new clinical trials. Results of a Phase I dose-escalation study, published in 2002, in which Rev- imid (CC-5013) achieved response or stabilization in 71 percent of patients (17/24) generated considerable excite- ment about the immunomodulating drug. “Revimid appears to be more potent against multiple myeloma when com- pared to thalidomide in-vitro and at least as active in patients, without side effects such as somnolence and constipation,” says Dr. Hussein, principal ...

What is a Telephone Education Workshop? Cancer Care ’s free Telephone Education Workshops are educational seminars that are conducted over the phone. The workshops are a way for people from across the country and internationally to learn about cancer-related issues from the convenience of their home or office. Leading experts in oncology provide the most up-to- date information on the telephone. How do I participate? All you need is a telephone to participate in a Telephone Education Workshop. Participation is free, and no phone charges apply. How do I register? You may mail the registration form provided to CancerCare or register online at www.cancercare.org. After you have registered, you will receive a packet of information and instructions. Controlling Cancer Pain: What You Need to Know to Get Relief Wednesday ...

MMRF www.multiplemyeloma.org email: themmrf@themmrf.com Accelerating the Search for a Cure Multiple Myeloma : a Disease Overview M M R F. Multiple Myeloma Research Foundation Page 2 M M R F. A c c e l e r a t i n g t h e S e a r c h f o r a C u r e The Multiple Myeloma Research Foundation (MMRF) is a nonprofit foundation driven by a sin- gle purpose: to accelerate the search for a cure for multiple myeloma . The MMRF focuses on 5 goals: Raising awareness of multiple myeloma Funding research in the field of multiple myeloma Fostering collaboration among researchers worldwide Providing information to patients and family members Advocating optimal patient care Multiple Myeloma Research Foundation (MMRF) 11 Forest Street New Canaan, CT 06840 Phone: 203-972-1250 Fax: 203-972-1259 ...

The Multiple Myeloma Research Foundation (MMRF) is an international non-profit foundation driven by a single purpose: to accelerate the search for a cure for multiple myeloma . The MMRF focuses on five goals: Raising awareness of multiple myeloma Funding research in the field of multiple myeloma Fostering collaboration among researchers worldwide Providing information to patients and family members Advocating optimal patient care Multiple Myeloma Research Foundation (MMRF) 3 Forest Street New Canaan, CT 06840 Phone: 203-972-1250 Fax: 203-972-1259 Web: www.multiplemyeloma.org E-mail: themmrf@themmrf.org A special thanks to GAMBRO, BCT who has provided an unrestricted educational grant to support this brochure Page 2 What is Multiple Myeloma ? Multiple myeloma ...

MULTIPLE MYELOMA - All Sections MULTIPLE MYELOMA What Is Cancer? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer, they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells develop because of damage to DNA. This substance is in every cell and directs all its activities. Most of the time when DNA becomes damaged, either the cell dies or is able to ...

THE NEW LIGHT OF MYANMAR Saturday, 12 June, 2004 13 World “AIDS” Campaign urges G-8 to honour promises L ONDON , 10 June — The World AIDS Campaign (WAC) called on G-8 govern- ments on Thursday to help save millions of lives by honouring commitments they made in signing the United Nations global AIDS compact three years ago. In a call for action due to be presented at the summit, the World AIDS Campaign urged governments to ensure integrated approaches to HIV and AIDS programmes and intensify support for research and development into effective and safe medicines. It also asked governments to increase their funding for overseas development assistance aimed at reducing poverty — a key factor in the spread of HIV across the world. “Twenty years after the discovery of the HIV virus, the need to bring this devastating epidemic in the developing world ...

ORAL MELPHALAN, PREDNISONE, AND THALIDOMIDE FOR NEWLY DIAGNOSED MYELOMA PATIENTS A. Palumbo*, A. Bertola*, P. Musto°, M. Nunzi°, V. De Stefano°, L. Catalano°, T. Caravita°, C. Cangialosi°, S. Bringhen*, M. Boccadoro*. Divisione Universitaria di Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino–Italy* , and the Italian Multiple Myeloma Study Group° Page 2 ABSTRACT Background: Thalidomide (T) alone or in combination has been tested and proved effective in multiple myeloma . No data are available on the association of T with oral melphalan and prednisone (MP) in newly diagnosed patients. Here, we evaluated the potential additive and synergistic effect of the combination melphalan, prednisone, and thalidomide (MPT). Methods: Between June 2002 and June 2003, 42 patients (median age 72, range 61–80) with newly diagnosed symptomatic ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? JUNE NOTES Meeting: Tuesday June 15, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: Video: Alternative Healing, Dr. Lewis Mehl-Madrona, MD, PhD Coordinator for Integrative Psychiatry and System Medicine Program in Integrative Medicine University of Arizona Group Discussion More Information: ...

Myeloma Printing of this publication is made possible by an education grant provided by Novartis. Page 2 Introduction This booklet provides information about myeloma for patients and their families. A glossary at the end of the booklet may help the reader understand technical terms. We hope this information is of assistance and would welcome comments as to the clarity of the information provided and the omission of information that would have been helpful. Each year, about 14,000 persons in the United States learn that they have myeloma . Myeloma may be called by several names, including plasma cell dyscrasia, plasma cell myeloma , myelomatosis, and multiple myeloma . The disease may be referred to as Kahler’s disease, especially in Europe, in recognition of the physician who first published the most comprehensive ...

IMMUNOMEDICS REPORTS ADVANCES IN LYMPHOMA AND MULITPLE MYELOMA THERAPY AT THE 40 th MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY New Orleans, LA, June 7, 2004 - Immunomedics, Inc. (Nasdaq:IMMU) announced today that two potential products showed promising activity in the treatment of aggressive non-Hodgkin’s lymphoma (NHL), and that a new product candidate is showing high activity in a human multiple myeloma animal model. A pilot clinical study of epratuzumab, Immunomedics’ humanized anti-CD22 monoclonal antibody, in combination with rituximab and CHOP chemotherapy (ER- CHOP), was studied in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) to assess safety and activity ( Poster 6580 ). Conducted by the Eastern Oncology Cooperative Group (ECOG) of the National Cancer Institute at the Mayo Clinic in Rochester, MN, and the University of Wisconsin ...

• First treatment modality in MM patients was 87% HD and 13% PD, without difference between age groups. Only 1.1% received a transplant while on RRT. • Figure 3 shows the crude patient survival of MM patients compared to other dialysis patients. Median survival in the MM group was 11 months. Main causes of death were: malignancy 38%, cardiovascular 16% and infection 16%. • Figure 4 shows that, adjusted for age and gender, MM patients had a 2.8 times (95%CI 2.6-3.0) higher risk of death compared to other dialysis patients. Adjusted dialysis patient survival did not change with time. Results • 906 patients started RRT for MM, median age 68 year, 57% male. • Mean age at start of RRT increased from 64 year in the 1985-1989 cohort to 67 year in the 1995-1999 cohort. • Crude RRT treated MM incidence increased from 0.4 pmp in the 1985-1988 cohort to 1.6 pmp in 1997-1999 cohort. • Figure 1 shows the ...

184 www.blackwellpublishing.com/journals/afm LETTER TO THE EDITOR Asia Pacific Family Medicine 2003; 2 : 184 Blackwell Science, LtdOxford, UKAFMAsia Pacific Family Medicine1444-1683© 2003 Blackwell Publishing Asia Pty LtdSeptember 200223184Letter to the EditorLetter to the EditorLetter to the Editor Accepted for publication 7 June 2003. LETTER TO THE EDITOR Atypical presentation of myeloma General Practice is fascinating because of the variety of cases and the wealth of clinical material that a Family Physician is in a fortunate position to see and help. Doctors working in very few specialties have first hand access to such a vast array of clinical cases in this era of specialization. This unique position of Family Physi- cians has its advantages and disadvantages. The disad- vantage is that it is obligatory in order to be a good Family Physician to keep ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? MAY NOTES Meeting: Tuesday May 18, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: James F. Cleary, MD, FAChPM Medical Director, Palliative Medicine Services UW Comprehensive Cancer Center, UW Hospital and Clinics President-Elect American Academy of Hospice and Palliative Medicine More Information: Chuck Koval &nb...

Nursing Considerations for the Treatment of LATE STAGE MULTIPLE MYELOMA www.oesweb.com CE MONOGRAPH Page 2 Page 3 NURSING CONSIDERATIONS FOR THE TREATMENT OF LATE STAGE MULTIPLE MYELOMA Table of Contents About This Publication . .4 Target Audience .5 Program Goal .5 Learning Objectives . .5 Continuing Education .5 Instructions for Obtaining Continuing Education . .5 Editor and Author Information . .6 Disclosure Information . .6 Overview . .7 Case Example . .7 Clinical Presentation of Multiple Myeloma .9 Treatment Challenges and Options .11 Novel Agents . .14 Nursing Implications in Caring for Patients with Multiple Myeloma .23 Summary .24 References . .25 Resources . .28 Post-Test Questions .30 Post-Test Answer Sheet . .32 Continuing Education ...

Mayo Clin Proc, March 2004, Vol 79 410 Keratopathy of Multiple Myeloma Mayo Clin Proc . 2004;79:410-412 410 © 2004 Mayo Foundation for Medical Education and Research Case Report From the Section on Human Biochemical Genetics, Medical Genet- ics Branch, National Human Genome Research Institute (R.K., I.B., W.A.G.) and Ophthalmic Genetics Branch, National Eye Institute (M.I.K.-K.), National Institutes of Health, Bethesda, Md; and Section of Hematology/Oncology, Riverside Methodist Hospital, Columbus, Ohio (S.C.B.). Individual reprints of this article are not available. Address corre- spondence to Robert Kleta, MD, PhD, 10 Center Dr, MSC 1851, Bldg 10, Room 10C-107, NHGRI, NIH, Bethesda, MD 20892-1851 (e-mail: kletar@mail.nih.gov). Keratopathy of Multiple Myeloma Masquerading as Corneal Crystals of Ocular Cystinosis R OBERT ...

myeloma TESTIMONIAL: MULTIPLE MYELOMA Patient: Clinton Carl, North Carolina Treatment Date: January 2003 Testimonial Date: June 2003 Diagnosis Date: July 1999 Age: 76 In July 1999, my husband, Clinton was given a complete physical and several areas were flagged abnormal in his blood work. In July 2000 he was officially diagnosed with Multiple Myeloma . After seeing the oncologist and listening to the traditional method of treatment, Clinton decided not to go the route of chemotherapy and radiatio n as outlined to him, but instead to try alternative medicine?which he did until Nov. 2002. Then, by referral, he met a MD who specializes in chelation and naturopathy. She offered several different treatments including H2O2, Vit C and other nutritional IVs as well as blood photoluminescence ...

myeloma Renal Failure Should Not Exclude Multiple Myeloma Patients from Receiving Autologous Stem Cell Transplants Source: 411Cancer.com "Cancer Experts leading the way to optimal cancer care." 10/01/2001 Renal failure should not exclude patients from undergoing autologous stem cell transplants, as this procedure appears to be safe and effective treatment for patients with multiple myeloma who have renal failure, according to a recent article published in the British Journal of Haematology. There are approximately 40,000 people in the United States living with multiple myeloma with 14,000 new cases of multiple myeloma diagnosed each year in the United States, making it the second most common blood cancer. Multiple myeloma is a cancer involving important immune (infection-fighting) cells called plasma cells. Plasma cells aid the body in fighting ...

myeloma Hematopoietic Cell Transplantation for Multiple Myeloma William I. Bensinger, MD Studies have shown that autologous hematopoietic stem cell transplantation has improved response rates and survival for selected patients with multiple myeloma . Background: Multiple myeloma (MM) is a malignant plasma cell disorder with a median survival of three years. Despite the development of numerous conventional chemotherapy regimens and interferons, there has been little progress in improving the survival of patients with MM. Very high-dose chemoradiotherapy and autologous or allogeneic hematopoetic stem cell transplantation (HSCT) can result in high complete remission rates, even in patients with advanced disease. Methods: A prospective, randomized study has shown that autologous HSCT results in superior response rates, progression-free survival, and disease-free survival compared with ...

Myeloma - An Introduction International Myeloma Foundation (UK) Page 2 This introduction is for people who have been diagnosed with myeloma , their families and friends. It provides a brief overview of myeloma , its treatment and management. If you would like a more detailed overview, IMF (UK) produce a guide called ' Myeloma - Your Essential Guide'. IMF (UK) also produce a comprehensive range of guides and factsheets covering all aspects of myeloma , its treatment and management. If you would like to speak to someone about any aspect of myeloma and its treatment or management please call our freephone helpline on 0800 980 3332 for immediate access to information and support. Your call will be answered by specialist nurses who are supported by medical and scientific advisors.The helpline is open Monday to ...

haematologica 2004; 89(5):May 2004 Editorials, Comments & Views 519 institution. Bone Marrow Transpl 2000;26:845-9. 16. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive ther- apy in patients with responsive multiple myeloma . Bone Mar- row Transplant 2001;27:1037-43. 17. Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, et al. Quantitative molecular monitoring of minimal residual disease heralds relapse in patients with multiple myeloma . Haemato- logica 2004; 89:53-62. 18. Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma : predictors of com- plete remission. Bone Marrow Transplant 2004;33:61-4. 19. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal resid- ual disease monitoring ...

haematologica 2004; 89(5):May 2004 517 Moving forward in myeloma research During the last two decades there has been impres- sive steps forward in myeloma research. This has been due to several facts: (i) an increasing number of investigators and specialized institutions devoted to clinical and laboratory research in this disease, (ii) the role of two Myeloma Foundations, the Interna- tional Myeloma Foundation (IMF) and the Multiple Myeloma Research Foundation (MMRF) supporting both research and patient care, (iii) the introduction of high-dose therapy/stem cell support leading to complete remission in a significant proportion of patients offering the hope of long-lasting disease control, (iv) better supportive measures (bisphospho- nates, erythropoietin) and (v) the availability of effec- tive anti- myeloma drugs (thalidomide, IMiDs, borte- zomib) with ...

haematologica 2004; 89(5):May 2004 547 [haematologica] 2004;89:547-551 P HILIPPE M OREAU N ELLY R OBILLARD H ERVE A VET -L OISEAU D ANIELLE P INEAU N ADINE M ORINEAU N OEL M ILPIED J EAN -L UC H AROUSSEAU R EGIS B ATAILLE Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma C D45, the first receptor-like protein tyrosine phosphatase expressed on all nucleated hematopoietic cells, is a critical regulator ...

haematologica 2004; 89(5):May 2004 628 5. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Rela- tionship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138:891-7. 6. Drucker L, Gronich N, Radnay J, Shapira H, Lishner M. Sim- vastatin induces death of multiple myeloma cell lines. Amer- ican Society of Hematology. Philadelphia; PA: USA. 2002. 7. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. ASCO 2003. 8. Durie BGM, Mundy GR. Statin use and the likelihood of bone disease in newly diagnosed myeloma . American Society of Hematology. Philadelphia; PA: USA. 2002. 9. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9. 10. LaCroix AZ, Cauley JA, Pettinger ...

Myeloma - Your Essential Guide International Myeloma Foundation (UK) Page 2 E-mail:TheIMF@ myeloma .org.uk Introduction Aims of this guide To help you understand more about myeloma and its treatment To help you to make informed treatment decisions To provide information to carers and family members This guide is written for patients with myeloma , their families and friends. It provides information on myeloma , its treatment and management. It is intended to help you understand the disease and to make informed decisions about your care and treatment options. It focuses on the most frequently used myeloma treatments but does not cover all treatments in detail.You may prefer to read only the sections that apply to you; each section is self-contained to allow you to do this.The quick reference index will help you find some of ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORT GROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? APRIL NOTES Meeting: Tuesday April 20, 2004 UW Health - West Clinic 451 Junction Road Time: 3:30 ? 5:30 PM Madison, WI 53717-2656 Program: Ask the Pharmacist--Joe Thiesen, Pharmacist Pharmacy - Oncology UW Hospital & Clinics More Information: Chuck Koval ...

1 TITLE Microenvironment Factors Do Not Afford Myeloma Cell Lines Protection From Simvastatin. AUTHORS Alla Osadchy, Liat Drucker, Judith Radnay, Hava Shapira, Michael Lishner. INSTITUTION AFFILIATION Oncogenetic Laboratory (AO, LD, ML), Hematology Laboratory (JR, HS) and Department of Internal Medicine (AO, ML), Sapir Medical Center, Meir Hospital, Kfar Sava and Sackler Faculty of Medicine (ML), Tel-Aviv University, Tel-Aviv, Israel. CORRESPONDING AUTHOR Liat Drucker Ph.D., Oncogenetic Laboratory, Sapir Medical Center, Meir Hospital, Kfar Sava, 44281, Israel. Phone: 972-9-7472466; Fax: 972-9-7472369; E-mail: Druckerl@clalit.org.il RUNNING TITLE Cytokines do not protect MM from Sim Page 2 2 ABSTRACT Background : The intensive interactions of myeloma cells (MM) with microenvironmental components of ...

RESEARCH TEAM CLOSING IN ON LINK BETWEEN MYELOMA AND BONE DESTRUCTION For the last few years, researchers at the Myeloma Institute for Research and Therapy have used live laboratory mice lacking immune systems, known as the severe combined immunodeficient-human (SCID- hu) host system, to examine the growth cycle of multiple myeloma cells in human bones. The SCID-hu model was developed in the late ‘70s to study the normal formation of blood and was later used to research leukemia treatments. Joshua Epstein, D. Sc. and Shmuel Yaccoby, Ph.D. have overseen the project since its inception in 1997. Epstein and Yaccoby implanted small human bones into mice, creating a human bone marrow microenvironment. The special laboratory mice lack immune systems and therefore do not reject foreign tissues. Because myeloma cells grow only in the bone ...